Stelis Biopharma’s flagship facility receives EIR from USFDA
The company is excited about the strategic progress that the company has made so far and are confident of delivering better business outcomes
The company is excited about the strategic progress that the company has made so far and are confident of delivering better business outcomes
This donation will allow the continuation of the cycle of vaccination for children foreseen within the national immunization program carried out by the Ministry of Public Health of Cuba
India's G20 Presidency will focus on three main priorities: Health Emergencies Prevention, Preparedness and Response (One Health & AMR); Access and Availability to Affordable Medical Countermeasures (Vaccines, Therapeutics, and Diagnostics); and Digital Health
The top 15 Indian pharma players have continued to experience anaemic growth in the US market over the five years ended FY22
New facility is based at Lonza’s Bend, Oregon (US) site, a Center of Excellence for bioavailability enhancement
Dolutegravir and Rilpivirine Tablets, 50 mg/25 mg, (RLD Juluca) had estimated annual sales of US $666 million in the US (IQVIA MAT September 2022)
A First of its Kind Initiative in Mahbubnagar District for Medical Officers, ANM, Anganwadi workers for prevention of Thalassemia and Sickle Cell anemia as part of Antenatal screening of pregnant women project
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad, India
Dr. Reddy’s will manufacture the Active Pharmaceutical Ingredient and finished drug at its facilities approved by USFDA
The company was chosen for this transformative exercise due to its deep expertise in the healthcare vertical, coupled with its digital engineering and cloud capabilities, a vast partner network, and long-term relationship with the client
Subscribe To Our Newsletter & Stay Updated